Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study
-
Published:2020-05-26
Issue:4
Volume:123
Page:619-623
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Cöktü Sümeyye,Spix Claudia,Kaiser Melanie,Beygo Jasmin,Kleinle Stephanie,Bachmann Nadine,Kohlschmidt Nicolai,Prawitt Dirk,Beckmann Alf,Klaes Ruediger,Nevinny-Stickel-Hinzpeter Claudia,Döhnert Steffi,Kraus Cornelia,Kadgien Gundula,Vater Inga,Biskup Saskia,Kutsche Michael,Kohlhase Jürgen,Eggermann Thomas,Zenker Martin,Kratz Christian P.
Abstract
Abstract
Background
Beckwith-Wiedemann syndrome (BWS) is a cancer predisposition syndrome caused by defects on chromosome 11p15.5. The quantitative cancer risks in BWS patients depend on the underlying (epi)genotype but have not yet been assessed in a population-based manner.
Methods
We identified a group of 321 individuals with a molecularly confirmed diagnosis of BWS and analysed the cancer incidence up to age 15 years and cancer spectrum by matching their data with the German Childhood Cancer Registry.
Results
We observed 13 cases of cancer in the entire BWS cohort vs 0.4 expected. This corresponds to a 33-fold increased risk (standardised incidence ratio (SIR) = 32.6; 95% confidence interval = 17.3-55.7). The specific cancers included hepatoblastoma (n = 6); nephroblastoma (n = 4); astrocytoma (n = 1); neuroblastoma (n = 1) and adrenocortical carcinoma (n = 1). The cancer SIR was highest in patients with a paternal uniparental disomy of 11p15.5 (UPDpat). A high cancer risk remained when cases of cancer diagnosed prior to the BWS diagnosis were excluded.
Conclusions
This study confirms an increased cancer risk in children with BWS. Our findings suggest that the highest cancer risk is associated with UPDpat. We were unable to confirm an excessive cancer risk in patients with IC1 gain of methylation (IC1-GOM) and this finding requires further investigation.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference25 articles.
1. Brioude, F., Kalish, J. M., Mussa, A., Foster, A. C., Bliek, J., Ferrero, G. B. et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat. Rev. Endocrinol. 14, 229–249 (2018). 2. Mussa, A., Russo, S., De Crescenzo, A., Chiesa, N., Molinatto, C., Selicorni, A. et al. Prevalence of Beckwith-Wiedemann syndrome in North West of Italy. Am. J. Med. Genet. A 161A, 2481–2486 (2013). 3. Eggermann, T., Perez de Nanclares, G., Maher, E. R., Temple, I. K., Tumer, Z., Monk, D. et al. Imprinting disorders: a group of congenital disorders with overlapping patterns of molecular changes affecting imprinted loci. Clin. Epigenetics 7, 123 (2015). 4. Mussa, A., Molinatto, C., Baldassarre, G., Riberi, E., Russo, S., Larizza, L. et al. Cancer risk in Beckwith-Wiedemann syndrome: a systematic review and meta-analysis outlining a novel (epi)genotype specific histotype targeted screening protocol. J. Pediatr. 176, 142–149. e141 (2016). 5. Maas, S. M., Vansenne, F., Kadouch, D. J., Ibrahim, A., Bliek, J., Hopman, S. et al. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am. J. Med. Genet. A 170, 2248–2260 (2016).
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|